Skip to main content
SpringerLink
Log in

What are the effects of cyclooxygenase-2-specific inhibitors on the small bowel?

  • Practice Point
  • Published:

From Nature Clinical Practice Gastroenterology & Hepatology

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Scheiman JM (2003) Gastroduodenal safety of cyclooxygenase-2 specific inhibitors. Curr Pharm Des 9: 2197–2206

    Article  CAS  Google Scholar 

  2. Chan FK et al. (2002) Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 347: 2104–2110

    Article  CAS  Google Scholar 

  3. Lanas A (2003) Celecoxib versus diclofenac and omeprazole to prevent recurrent ulcer bleeding. N Engl J Med 348: 2464–2466

    Article  Google Scholar 

  4. Laine L et al. (2003) Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology 124: 288–292

    Article  CAS  Google Scholar 

  5. Fendrick AM (2004) COX-2 inhibitor use after Vioxx: Careful balance or end of the rope? Am J Manag Care 11(Pt 1): 740–741

    Google Scholar 

Download references

Acknowledgements

The synopsis was written by Rachel Jones, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Professor of Medicine, Division of Gastroenterology and Director of Endoscopic Research at the University of Michigan, MI, USA

    James M Scheiman

Authors
  1. James M Scheiman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to James M Scheiman.

Ethics declarations

Competing interests

JM Scheiman is a Consultant for AstraZeneca, Merck, Novartis, TAP Pharmaceutical Products Inc, Pfizer and The GI Company. He has also received grants/research support in the past from AstraZeneca, Pfizer and Merck.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Scheiman, J. What are the effects of cyclooxygenase-2-specific inhibitors on the small bowel?. Nat Rev Gastroenterol Hepatol 2, 212–213 (2005). https://doi.org/10.1038/ncpgasthep0174

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpgasthep0174

  • Springer Nature Limited

Search

Navigation